Literature DB >> 7961551

Motor and mental side effects of clozapine.

J Gerlach1, L Peacock.   

Abstract

Long-term experience with clozapine has shown that the agent has a motor and mental side effect profile that is distinct in many ways from classical neuroleptics. It can produce a parkinsonian-like bradykinesia and mild akathisia, but no rigidity and rarely tremor. In patients with tardive dyskinesia induced by other neuroleptics, clozapine permits the dyskinesia to disappear in about half the cases. That clozapine may induce tardive dyskinesia in extremely rare cases cannot be excluded, but it seems more likely that this tardive dyskinesia in clozapine-treated patients is due to previous treatment with classical neuroleptics. The earlier clozapine is started, the less chance for development of tardive dyskinesia. As do other neuroleptics, clozapine can elicit sedation and asthenia, but corresponding to the motoric extrapyramidal syndrome, clozapine causes emotional indifference ("mental parkinsonism"), depression, and restlessness to a significantly lesser degree, which may be of importance in the higher compliance seen with this drug.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7961551

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  12 in total

1.  Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study.

Authors:  Itzhak Kimiagar; Evgenia Dobronevsky; Tatiana Prokhorov; Ala Miniovitz; Jose M Rabey
Journal:  J Neurol       Date:  2011-11-09       Impact factor: 4.849

Review 2.  Tolerability of atypical antipsychotics.

Authors:  C Stanniland; D Taylor
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

3.  Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis.

Authors:  J F Guest; R F Cookson
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

Review 4.  Conventional versus novel antipsychotics: changing concepts and clinical implications.

Authors:  G Remington; S A Chong
Journal:  J Psychiatry Neurosci       Date:  1999-11       Impact factor: 6.186

Review 5.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 6.  Effects of newer antipsychotics on extrapyramidal function.

Authors:  Daniel Tarsy; Ross J Baldessarini; Frank I Tarazi
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

7.  Dopamine D4 receptor-induced postsynaptic inhibition of GABAergic currents in mouse globus pallidus neurons.

Authors:  Ryong-Moon Shin; Masao Masuda; Masami Miura; Hiromi Sano; Takuji Shirasawa; Wen-Jie Song; Kazuto Kobayashi; Toshihiko Aosaki
Journal:  J Neurosci       Date:  2003-12-17       Impact factor: 6.167

8.  A Kinetic Model for Simultaneous Fit of Clozapine and Norclozapine Concentrations in Chronic Schizophrenic Patients during Long-Term Treatment.

Authors:  C Guitton; J M Kinowski; R Gomeni; F Bressolle
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 9.  Adverse effects of antipsychotic agents. Do newer agents offer advantages?

Authors:  D G Owens
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

10.  Managing antipsychotic-induced acute and tardive dystonia.

Authors:  M Raja
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.